跳至主要内容
临床试验/NCT04621812
NCT04621812Unknown不适用

Role of Fecal Microbiota in Predicting Graft Rejection and Sepsis Among Recipients of Living Donor Liver Transplant in First Year - An Observational Study.

Institute of Liver and Biliary Sciences, India1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2020年11月8日最近更新:
适应症

试验速览

阶段
不适用
入组人数
100
试验地点
1
主要终点
Development of CMV infection

研究概览

简要总结

Efficient immunosuppressive therapy and improved surgical techniques have developed liver transplantation as a well-established and life-saving treatment. The 1-year survival rate of approximately 85-90%. Acute cellular rejection (ACR) is one of the main causes of liver dysfunction (LD) after liver trans- plantation, occurring 30% to 70% of transplanted patients and potentially leading to allograft failure. In addition to ACR, presence of sepsis, drug injury, viral infections like CMV or recurrence of viral hepatitis is also other causes of graft dysfunction. Laboratory tests are commonly used as less invasive methods of monitoring allograft rejection, but they are not specific to rejection and are often elevated in other types of graft dysfunction too.

Till date the immunosuppressive regimen in liver transplant recipient is considered as an art in absence of an objective measures of the immune state. Therapeutic drug monitoring has little value in the assessment of the immune state and is always used as a supportive guide. The development of specific immune monitoring assays to measure the net immunosuppressive state in a transplant recipient would allow a more individualized therapeutic regimen Patients with altered gut microbiota had more chances of infection and longer course of hospital stay. Probiotics could mediate beneficial effects in graft rejection. Dysbiosis activates T cells through PAMPS and causes the inflammatory injury in the graft liver. The studies shown that lower Eubacteria, Bifidobacterium, Faecal bacterium and Lactobacillus with abundance of Enterococcus and Enterobacteriaceae. They restored to near normal after transplant in majority.

This is known that there is a dysbiosis in the natural history of ACLF or decompensated cirrhosis, and often correlated to complications like-endotoxemia, sepsis, worsening liver failure and poor survival. This has led to consider fecal microbiota modulation as an emerging therapy. Liver transplant and consequent recovery, there is over all change in the recipient homeostatic milieu as well as the immune milieu and the same may be happening to the gut flora too.It's well known that liver has animprint of resident gut flora. The preliminary rat model showed alteration of gut flora to predict the development acute cellular rejection before it happens. Similarly the risk of infection is more among transplant recipients with decreased microbial diversity after liver transplant. However the data is scanty and there is an urgent need to understand the mechanism..

The present study was necessitated in view of emerging role of gut microflora and its influence on immune remodeling for the prediction of infection, rejection and may be an early biomarker for the graft dysfunction. This may be of varied cause in liver transplant recipients along with its impact on overall immune status. Uniqueness of the present study will be to understand the mechanism of development of sepsis or graft dysfunction in due course of time using high-throughput tools of single cell analysis in whole blood and gut microbiota alterations among liver transplant recipient as a cause for graft dysfunction in first year of live donor liver transplant.

详细描述

Primary Objective:

To characterize the fecal microbiota changes over one year after living donor liver transplantation and its association with graft rejection and sepsis.

Secondary objectives :

  1. Incidence of graft dysfunction attributable to sepsis, rejection and CMV infection in first year of LDLT.
  2. To study the pre-LT immunological profile and its correlation with post-transplant rejection, immunosuppression requirements and restoration of immunosenescence.
  3. To correlate the dynamic changes in immune cells and cytokines in predicting graft rejection and sepsis.

STUDY DESIGN Type of study - Single centre, prospective, observational study Study population - consecutive 100 patients fulfilling the eligibility criteria and undergoing living donor liver transplant in ILBS between April 2020 to March 2022.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
12 Years 至 75 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Living donor Liver transplantation for ALF, ACLF, cirrhosis and its complications.
  • Age 12-75 years
  • Valid consent

排除标准

  • Deceased Donor Liver Transplants
  • Re-transplants
  • Simultaneous Liver-Kidney Transplants (SLKT)

结局指标

主要结局

Development of CMV infection

时间窗: 1 years

CMV DNA diagnosis is by RT PCR technique

Death

时间窗: 1 years

Development of rejection

时间窗: 1 years

Rejection dosgnosis is based on graft biopsy and histology - assessed by REJECTION ACTIVITY INDEX (RAI)

Development of sepsis

时间窗: 1 years

Sepsis diagnosis is based on positive cultures of the patient (Blood, urine, tip of catheter ), foci of infection by cross sectional imaging at any point of time

次要结局

  • Post LT complications requiring surgical interventions(1 years)
  • Number of patients who will undergo Retransplantation(1 years)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

招募中
不适用
Role of Fecal Microbiota in Predicting Graft Rejection and Sepsis Among Recipients of Living Donor Liver Transplant in First Year - An Observational Study.
CTRI/2020/11/028834Institute of Liver and Biliary Sciences
Unknown
3 期
Efficacy of Fecal Microbiota Transplantation for Inflammatory Bowel DiseaseConstipation (Excl Faecal Impaction)Ulcerative ColitisCrohn Disease
NCT02575040Saglik Bilimleri Universitesi Gulhane Tip Fakultesi60
招募中
1 期
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With CancerClinical Stage 0 Cutaneous Melanoma AJCC v8Clinical Stage I Cutaneous Melanoma AJCC v8Clinical Stage IA Cutaneous Melanoma AJCC v8Clinical Stage IB Cutaneous Melanoma AJCC v8Clinical Stage II Cutaneous Melanoma AJCC v8Clinical Stage IIA Cutaneous Melanoma AJCC v8Clinical Stage IIB Cutaneous Melanoma AJCC v8Clinical Stage IIC Cutaneous Melanoma AJCC v8Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8ColitisLung Non-Small Cell CarcinomaMalignant Genitourinary System NeoplasmMalignant Solid NeoplasmPathologic Stage 0 Cutaneous Melanoma AJCC v8Pathologic Stage I Cutaneous Melanoma AJCC v8Pathologic Stage IA Cutaneous Melanoma AJCC v8Pathologic Stage IB Cutaneous Melanoma AJCC v8Pathologic Stage II Cutaneous Melanoma AJCC v8Pathologic Stage IIA Cutaneous Melanoma AJCC v8Pathologic Stage IIB Cutaneous Melanoma AJCC v8Pathologic Stage IIC Cutaneous Melanoma AJCC v8Pathologic Stage III Cutaneous Melanoma AJCC v8Pathologic Stage IIIA Cutaneous Melanoma AJCC v8Pathologic Stage IIIB Cutaneous Melanoma AJCC v8Pathologic Stage IIIC Cutaneous Melanoma AJCC v8Pathologic Stage IIID Cutaneous Melanoma AJCC v8Pathologic Stage IV Cutaneous Melanoma AJCC v8Stage 0 Lung Cancer AJCC v8Stage I Lung Cancer AJCC v8Stage IA1 Lung Cancer AJCC v8Stage IA2 Lung Cancer AJCC v8Stage IA3 Lung Cancer AJCC v8Stage IB Lung Cancer AJCC v8Stage II Lung Cancer AJCC v8Stage IIA Lung Cancer AJCC v8Stage IIB Lung Cancer AJCC v8Stage III Lung Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8Stage IIIC Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8Stage IVB Lung Cancer AJCC v8
NCT03819296M.D. Anderson Cancer Center800
Unknown
2 期
Fecal Microbiota Transplantation on Type 2 Diabetes MellitusEfficiencyMethodology
NCT01790711The Second Hospital of Nanjing Medical University30
招募中
2 期
Fecal Microbiota Transplantation With Immune Checkpoint Inhibitors in Lung CancerMetastatic Lung Cancer
NCT05502913Soroka University Medical Center80